Advertisement
Screener

INMUNE BIO INC. (INMB) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

INMUNE BIO INC. Financing Cash Flow

INMUNE BIO INC. (INMB) reported Financing Cash Flow of $749.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06

  • INMUNE BIO INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $67.00K.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $22.27M, a 71.35% increase year-over-year.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $5.27M.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for fiscal 2025 was $27.61M, a 51.62% increase from fiscal 2024.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for fiscal 2024 was $18.21M.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for fiscal 2023 was -$4.22M, a 679.56% decline from fiscal 2022.
  • INMUNE BIO INC. net cash provided by (used in) financing activities for fiscal 2022 was $729.00K, a 99.24% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 3 month as first filedNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 6 month as first filedNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 9 month as first filedNet Cash Provided by (Used in) Financing Activities 12 monthNet Cash Provided by (Used in) Financing Activities 12 month as first filed
2026-06-30$749.00K
10-Q · filed 2026-08-06
2025-12-31$67.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$67.00K
derived: sum of 2 quarters · filed 2026-03-30
$22.34M
derived: sum of 3 quarters · filed 2026-08-06
$27.61M
10-K · filed 2026-03-30
2025-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$22.27M
derived: sum of 2 quarters · filed 2026-08-06
$27.55M
10-Q · filed 2025-10-30
$25.47M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$22.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$27.55M
10-Q · filed 2026-08-06
$25.47M
derived: sum of 3 quarters · filed 2026-08-06
$35.26M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$5.27M
10-Q · filed 2026-05-07
$3.20M
derived: sum of 2 quarters · filed 2026-05-07
$12.99M
derived: sum of 3 quarters · filed 2026-05-07
$25.98M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$2.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$7.71M
derived: sum of 2 quarters · filed 2026-03-30
$20.71M
derived: sum of 3 quarters · filed 2026-03-30
$18.21M
10-K · filed 2026-03-30
2024-09-30$9.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30
$22.79M
derived: sum of 2 quarters · filed 2025-10-30
$20.29M
10-Q · filed 2025-10-30
$17.79M
derived: sum of 4 quarters · filed 2025-10-30
2024-06-30$13.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$10.50M
10-Q · filed 2025-08-07
$8.00M
derived: sum of 3 quarters · filed 2025-08-07
2024-03-31-$2.50M
10-Q · filed 2025-05-08
-$5.00M
derived: sum of 2 quarters · filed 2025-05-08
2023-12-31-$2.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
-$4.22M
10-K · filed 2025-03-27
2023-09-30-$1.73M
10-Q · filed 2024-10-31
2022-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
$0.00
derived: sum of 2 quarters · filed 2024-03-28
$0.00
derived: sum of 3 quarters · filed 2024-03-28
$729.00K
10-K · filed 2024-03-28
2022-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01
$0.00
derived: sum of 2 quarters · filed 2023-11-01
$729.00K
10-Q · filed 2023-11-01
$729.00K
derived: sum of 4 quarters · filed 2023-11-01
2022-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07
$729.00K
10-Q · filed 2023-08-07
$729.00K
derived: sum of 3 quarters · filed 2023-08-07
$53.67M
derived: sum of 4 quarters · filed 2023-08-07
2022-03-31$729.00K
10-Q · filed 2023-05-03
$729.00K
derived: sum of 2 quarters · filed 2023-05-03
$53.67M
derived: sum of 3 quarters · filed 2023-05-03
$68.62M
derived: sum of 4 quarters · filed 2023-05-03
2021-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02
$52.94M
derived: sum of 2 quarters · filed 2023-03-02
$67.89M
derived: sum of 3 quarters · filed 2023-03-02
$96.36M
10-K · filed 2023-03-02
2021-09-30$52.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02
$67.89M
derived: sum of 2 quarters · filed 2022-11-02
$96.36M
10-Q · filed 2022-11-02
$96.36M
derived: sum of 4 quarters · filed 2022-11-02
2021-06-30$14.95M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03
$43.41M
10-Q · filed 2022-08-03
$43.41M
derived: sum of 3 quarters · filed 2022-08-03
$66.66M
derived: sum of 4 quarters · filed 2022-08-03
2021-03-31$28.46M
10-Q · filed 2022-05-05
$28.46M
derived: sum of 2 quarters · filed 2022-05-05
$51.70M
derived: sum of 3 quarters · filed 2022-05-05
$52.37M
derived: sum of 4 quarters · filed 2022-05-05
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03
$23.24M
derived: sum of 2 quarters · filed 2022-03-03
$23.90M
derived: sum of 3 quarters · filed 2022-03-03
$23.89M
10-K · filed 2022-03-03
$23.90M
10-K · filed 2021-03-04
2020-09-30$23.24M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03
$23.90M
derived: sum of 2 quarters · filed 2021-11-03
$23.89M
10-Q · filed 2021-11-03
$23.90M
10-Q · filed 2020-11-05
$23.89M
derived: sum of 4 quarters · filed 2021-11-03
2020-06-30$664.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04
$655.00K
10-Q · filed 2021-08-04
$655.49K
10-Q · filed 2020-08-05
$655.00K
derived: sum of 3 quarters · filed 2021-08-04
$655.00K
derived: sum of 4 quarters · filed 2021-08-04
2020-03-31-$9.00K
10-Q · filed 2021-05-05
-$9.36K
10-Q · filed 2020-05-14
-$9.00K
derived: sum of 2 quarters · filed 2021-05-05
-$9.00K
derived: sum of 3 quarters · filed 2021-05-05
$4.95M
derived: sum of 4 quarters · filed 2021-05-05
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04
$0.00
derived: sum of 2 quarters · filed 2021-03-04
$4.96M
derived: sum of 3 quarters · filed 2021-03-04
$12.21M
10-K · filed 2021-03-04
2019-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$4.96M
derived: sum of 2 quarters · filed 2020-11-05
$12.21M
10-Q · filed 2020-11-05
$12.21M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$4.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05
$12.21M
10-Q · filed 2020-08-05
$12.21M
derived: sum of 3 quarters · filed 2020-08-05
$12.21M
derived: sum of 4 quarters · filed 2020-08-05
2019-03-31$7.25M
10-Q · filed 2020-05-14
$7.25M
derived: sum of 2 quarters · filed 2020-05-14
$7.25M
derived: sum of 3 quarters · filed 2020-05-14
$7.25M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11
$0.00
derived: sum of 2 quarters · filed 2020-03-11
$0.00
derived: sum of 3 quarters · filed 2020-03-11
$900.00K
10-K · filed 2020-03-11
2018-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08
$0.00
derived: sum of 2 quarters · filed 2019-11-08
$900.00K
10-Q · filed 2019-11-08
2018-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$900.00K
10-Q · filed 2019-08-09
2018-03-31$900.00K
10-Q · filed 2019-05-15
2017-12-31$2.06M
10-K · filed 2019-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21
EXOZYMES INC. (EXOZ)United States$0.058B
Tevogen Inc. (TVGN)United States$0.049B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Instil Bio, Inc. (TIL)United States$0.048B-1.73
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
BioStem Technologies, Inc. (BSEM)United States$0.069B